Clinical Trials Logo

Infarction clinical trials

View clinical trials related to Infarction.

Filter by:

NCT ID: NCT05696379 Completed - Clinical trials for Acute Myocardial Infarction (AMI)

Angiography Derived Index of Microcirculatory Resistance in Patients With Acute Myocardial Infarction

Start date: June 1, 2017
Phase:
Study type: Observational

Coronary microcirculatory dysfunction has been known to be prevalent even after successful revascularization of acute myocardial infarction (AMI) patients, and has been shown to be associated with poor prognosis. Angiography derived index of micro-circulatory resistance (Angio-IMR) is a novel pressure-wire free approach to assess coronary microvascular disease with great diagnostic performance. The current study will further investigate the prognostic value of Angio-IMR in patients with AMI in multicenter retrospective cohort.

NCT ID: NCT05692752 Completed - Clinical trials for Myocardial Infarction, Acute

Expression of microRNA-133a and microRNA-208b in Acute Myocardial Infarction

Start date: December 28, 2022
Phase:
Study type: Observational [Patient Registry]

Cardiac-enriched micro-RNAs (miRNAs), micro RNA 208b and 133a(MiR-208b, MiR-133a)) corresponds to the health and disorders of the cardiovascular system. An intron of the cardiac myosin heavy chain gene MYH7 encodes miR-208b. It is found on chromosome 14 in humans. Identify new diagnostic biomarkers based on miRNAs, researchers examine the expression of miR-133a and 208b at various time points (04 hours, 08 hours, 12 hours, 24 hours, 48 hours) following the development of the infarct and compared it to the traditional myocardial infarction biomarkers cardiac troponine (cTnl) and Creatine kinase-MB (CK-MB).

NCT ID: NCT05670249 Completed - Cerebellar Stroke Clinical Trials

Decompressive Craniectomy in Patients With Cerebellar Infarction

DEMCI
Start date: January 5, 2016
Phase: N/A
Study type: Interventional

The investigators aimed to evaluate the outcome in participants up to 80 years of age with space-occupying cerebellar infarction treated with suboccipital decompressive craniectomy (SDC) compared to medical therapy alone.

NCT ID: NCT05649696 Completed - Clinical trials for ST-segment Elevation Myocardial Infarction (STEMI)

Prolonged Clinical Follow-up of OPTIMA-5

Start date: October 29, 2021
Phase: Phase 4
Study type: Interventional

The OPTIMA-5 trial is a prospective, multi-center, randomized, patient blinded, controlled trial comparing a single bolus of half-dose recombinant staphylokinase (r-SAK) with normal saline (NS) in patients with ST-segment elevation myocardial infarction (STEMI) presenting ≤12 hours of symptom onset and expected to undergo primary percutaneous coronary intervention (PPCI) within 120 minutes. The results of OPTIMA-5 showed that a single bolus r-SAK prior to PPCI for STEMI improves infarct related artery (IRA) patency and reduces infarct size without increasing major bleeding. On this basis, this study was designed to investigate the effect of the novel reperfusion strategy on 1-year outcomes of patients with STEMI.

NCT ID: NCT05639244 Completed - Clinical trials for Myocardial Infarction

Time Restricted Eating and Innate Immunity

SIGNATURE
Start date: November 17, 2022
Phase: N/A
Study type: Interventional

The goal of this cross over study is to investigate the effect of short term time restricted eating (TRE) on the innate immune system in patients with a history of myocardial infarction.

NCT ID: NCT05601310 Completed - STEMI Clinical Trials

Metabolic Characteristics of Type 2 Diabetes Mellitus Combined With Acute Myocardial Infarction: A Untargeted Metabolomics Study

Start date: May 23, 2017
Phase:
Study type: Observational

This study is a retrospective case-control study. In this study, through untargeted metabolomics, investigators identified several specific changed serum metabolites in T2DM patients with or without AMI and their functions/category. Moreover, researchers selected several endogenous candidate biomarkers with larger fold change for validation in expanded population to find biomarkers which effectively predict the development of STEMI in patients with T2DM.

NCT ID: NCT05536960 Completed - Clinical trials for Atheroscleroses, Coronary

Dotatate to Locate Coronary Plaques at High-risk of Myocardial Infarction

DOLPHIN
Start date: September 9, 2022
Phase: N/A
Study type: Interventional

To assess whether vulnerable coronary plaques have more uptake of 68Ga-Dotatate than non-vulnerable plaques.

NCT ID: NCT05532917 Completed - Clinical trials for Myocardial Infarction

Cardiology Consultation in Noncardiac Surgery

Start date: January 15, 2022
Phase:
Study type: Observational [Patient Registry]

Recently, a predictive model has been developed to assess the risk of myocardial infarction or cardiac arrest (MICA) during and after surgery using the American Society of Surgeons' National Surgical Quality Improvement Program (NSQIP) database. In this MICA model, 180 hospital databases were used in 2007 and 2008 and included more than 200 000 patients. The Gupta score developed with this MICA model identified five predictors of perioperative myocardial infarction and cardiac arrest: type of surgery, functional status, creatinine increase (>130 mmol/L or >1.5 mg/dL), age, and American Association of Anesthesiologists (ASA) class. The Gupta score is presented as an interactive risk calculation program in the 2014 guideline of the ACC/AHA. The risk can be calculated simply and accurately at the bedside or clinic. The Gupta score is in spreadsheet format and can be downloaded online at http://www.surgicalriskcalculator.com/miorcardiacarrest. Unlike the previously used indexes, a scoring system has not been established. An estimate of the probability of myocardial infarction/cardiac arrest is provided for individual patients. In this study, the primary aim was to compare the frequency of cardiology consultation requests according to the use of the Gupta score. The secondary aim is to evaluate the perioperative clinical results (coronary angiography, ECHO, acute coronary syndrome, arrhythmia, 30-day mortality, etc.).SPSS 21.0 (Version 22.0, SPSS, Inc, Chicago, IL, USA) program will be used for statistical analysis. After applying the Shapiro-Wilk test for normality, the student's t-test will be used if the distribution is normal, and the Mann-Whitey U test will be used if the distribution is not normal. Fisher's exact test or chi-square test will be used for categorical variables. Results p<0.05 will be considered significant.

NCT ID: NCT05511649 Completed - Clinical trials for Acute Myocardial Infarction

New-Onset Atrial Fibrillation Complicating Acute Myocardial Infarction in China

NOAFCAMI-China
Start date: March 1, 2023
Phase:
Study type: Observational

To investigate the prognostic impacts of the atrial fibrillation burden (AFb) in acute myocardial infarction (AMI) patients who developed paroxysmal new-onset atrial fibrillation (NOAF) during the index AMI hospitalization.

NCT ID: NCT05487560 Completed - Clinical trials for Acute Coronary Syndrome or B Cerebral Infarction Requiring DAPT(Clopidogrel + Aspirin) for at Least 6 Months

An Observational Study to Evaluate the Incidence of MACCE According to Time Interval of Taking Medication in Patients With Acute Coronary Syndrome or Cerebral Infarction Who Received DAPT for the Secondary Prevention and Esomezol Cap for the Prevention of Gastrointestinal Bleeding

Start date: April 18, 2019
Phase:
Study type: Observational

This study is to evaluate the incidence rate of Major Adverse CardioCerebrovascular Events(MACCE) in Patients with Acute Coronary Syndrome or Cerebral Infarction Who Received DAPT for the secondary prevention and Esomezol Cap for the prevention of gastrointestinal bleeding.